β2-Glycoprotein I (β2-GPI) is a major antigen for anticardiolipin antibodies (aCL) induced in patients with antiphospholipid syndrome and their antigenic epitopes are cryptic. The epitopes appear on the surface of β2-GPI molecule only when β2-GPI interacts with lipid membranes containing negatively charged phospholipids or polyoxygenated polystyrene surface. Our data also indicated that CuSO4-oxidized low density lipoproteins (oxLDL) are subsequently targeted by β2-GPI and aCL; however, malonedialdehyde (MDA)-modified LDL were recognized neither by β2-GPI nor aCL. β2-GPI binding to LDL was rapidly increased by incubation with CuSO4. Oxidation of lipoproteins was accompanied with the increment of thiobarbituric acid-reactive substances (TBARS) and denature of apolipoprotein. Ligands on LDL for β2-GPI seemed to be intermediate oxidative derivatives which were extractable into the chloroform phase by Bligh and Dyer's extraction, but not MDA. Further, immune responses against β2-GPI, as an anti-atherogenic protein, were demonstrated to induce atherogenic effect in in vitro oxLDL uptake by macrophages.
McNeilHP, ChestermanCN, KrilisSA.Immunology and clinical importance of antiphospholipid antibodies.Adv Immunol1991; 49: 193–280.
4.
HarrisEN. Anti-cardiolipin antibodies: detection by radio-imunoassay and association with thrombosis in systemic lupus erythematosus.Lancet1983; 2: 1211–1214.
5.
McNeilHP, SimpsonRJ, ChestermanCN, KrilisSA.Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).Proc Natl Acad Sci USA1990; 87: 4120–4124.
6.
GalliM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.Lancet1990; 355: 1433–1547.
7.
MatsuuraE. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.Lancet1990; 336: 177–178.
8.
MatsuuraE. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.J Immunol1992; 148: 3885–3891.
9.
MatsuuraE, IgarashiY, YasudaT, TriplettDA.Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.J. Exp Med1994; 179: 457–462.
10.
RossR.The pathogenesis of atherosclerosis: a perspective for the 1990s.Nature1993; 362: 801–809.
11.
SteinbergD. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity.New Eng J Med1989; 320: 915–924.
12.
KriegerM.Structures and functions of multiligand lipoprotein receptors.Ann Rev Biochem1994; 63: 601–637.
13.
GoldsteinJL, HoYK, BasuSK, BrownMS.Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.Proc Natl Acad Sci USA1979; 76: 333–337.
14.
HenriksenTE, MahoneyEM, SteinbergD.Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins.Proc Natl Acad Sci USA1981; 78: 6499–6503.
15.
HenriksenTE, MahoneyEM, SteinbergD.Enhanced macrophage degradation of biologically modified low density lipoprotein.Arteriosclerosis1983; 3: 149–159.
16.
NishikawaK, AraiH, InoueK.Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages.J Biol Chem1990; 265: 5226–5231.
17.
Palinski. Low density lipoprotein undergoes oxidative modification in vivo.Proc Natl Acad Sci USA1989; 86: 1372–1376.
18.
SteinbrecherUP. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids.Proc Natl Acad Sci USA1984; 81: 3883–3887.
19.
PuurunenM. Antibodies to phospholipid binding proteins and occurrence of thrombosis in patients with systemic lupus erythematosus.Clin Immununol Immunopathol1996; 80: 16–22.
20.
SchultzeHE, HeideK, HaputH.Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums.Naturwissenschaften1961; 48: 719–724.
21.
WurmH.Beta2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles.Int J Biochem1984; 16: 511–515.
22.
PolzE.Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin-Sepharose. In: PeetersH (ed) Protides of Biological FluidsPergamon Press. Oxford, 1979, pp 817.
23.
PolzE, KostnerGM.The binding of β2-glucoprotein I to human serum lipoproteins: distribution among density fractions.FEBS Lett1979102: 183–186.
24.
NimpfJ. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I.Biochim Biophys Acta1986; 884: 142–149.
25.
SchousboeI.β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.Blood1985; 66: 1086–1091.
26.
NimpfJ, WurmH, KostnerGM.β2-glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation.Atherosclerosis1987; 63: 109–114.
27.
Palinski. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.Atherosclerosis1990; 10: 325–335.
28.
SalonenJT. Autoantibody against oxidized LDL and progression of carotid atherosclerosis.Lancet1992; 339: 883–887.
29.
VaaralaO. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus.Lancet1993; 341: 923–925.
30.
HasunumaY. Involvement of β2-glycoprotein I and anti-cardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages.Clin Exp Immunol1997; 107: 569–573.
31.
GeorgeJ. Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS).Clin Exp Immunol1997; 108: 227–233.
32.
UrowitzMB. The bimodal mortality pattern of systemic lupus erythematosus.Am J Med1976; 60: 221–225.
33.
HomcyCJ. Ischemic heart disease in systemic lupus erythematosus in the young patient: report of 6 cases.Am J Cardiol1982; 49: 478–484.
34.
AshersonRA, HarrisEN, GharaviA, HughesGRV.Myocardial infarction in systemic lupus erythematosus and ‘lupus-like’ disease.Arthritis Rheum1986; 29: 1292–1293.
